Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeks
Open Access
- 7 March 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (10) , e41728
Abstract
Increased weight has been observed among treatment-naïve-and-experienced people living with HIV initiating bictegravir (BIC) and dolutegravir (DTG). Here, we report changes in weight and body mass index (BMI) following switch to a BIC versus DTG-based regimen (DBR) through 144 weeks. This observational study collected demographics, clinical characteristics, weight, and BMI from virologically suppressed adults switched to BIC/emtricitabine/tenofovir alafenamide (TAF), emtricitabine/TAF plus DTG, DTG/abacavir/lamivudine, DTG/rilpivirine (RPV), and DTG/lamivudine 2 years prior to switch through 144 weeks post-switch. Linear spline models were fit to estimate and compare the trajectories of weight and BMI changes observed pre-and-post-switch. Adjusted piecewise linear mixed-effects models were fit to examine factors associated with weight and BMI change pre-and-post-switch. At week 144, switching to BIC/emtricitabine/TAF versus a DBR were both associated with lower annualized weight gain post-switch (‐0.88 kg/year vs −0.39 kg/year respectively, P = .15). DTG plus emtricitabine/TAF switches had the highest annualized weight gain (0.68 kg/year, 95% confidence interval: −0.32, 1.65) whereas, DTG/RPV switches had the lowest annualized weight gain (‐2.22 kg/year, 95% confidence interval: −3.69, −0.62) post-switch. DTG/RPV and BIC/emtricitabine/TAF switches were the only groups with significantly lower annualized weight gain post-switch at week 144. Baseline BMI < 18.5 kg/m2 was associated with the highest annualized weight gain post-switch, whereas switching from protease inhibitors and self-report of dieting were associated with the lowest annualized weight gain post-switch. At week 144, switching to a BIC versus DBR were both associated with lower annualized weight gain post-switch among a large and diverse cohort of treatment-experienced people living with HIV.Keywords
This publication has 31 references indexed in Scilit:
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIVNew England Journal of Medicine, 2019
- Behavioral Weight Loss: A Promising Treatment for Obesity in Adults with HIVAIDS and Behavior, 2019
- Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral TherapyClinical Infectious Diseases, 2019
- Do Integrase Inhibitors Cause Weight Gain?Clinical Infectious Diseases, 2019
- Behavioral and Cardiovascular Effects of a Behavioral Weight Loss Program for People Living with HIVAIDS and Behavior, 2019
- Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in AdultsJAMA, 2018
- Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialThe Lancet HIV, 2018
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trialThe Lancet HIV, 2018
- Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2017
- Dolutegravir and weight gainAIDS, 2017